Crossref
Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer
Human Gene Therapy Clinical Development · 2014
DOI: 10.1089/hum.2013.181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy Clinical Development, 2014. Verfasst von Ellen Schenk und 5 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Schenk, E., Essand, M., Kraaij, R., Adamson, R., Maitland, N., & Bangma, C. H. (2014). Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer. Human Gene Therapy Clinical Development. https://doi.org/10.1089/hum.2013.181
Vancouver
Schenk E, Essand M, Kraaij R, Adamson R, Maitland N, Bangma CH. Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer. Human Gene Therapy Clinical Development. 2014. doi:10.1089/hum.2013.181
BibTeX
@article{Schenk2014,
author = {Schenk, Ellen and Essand, Magnus and Kraaij, Robert and Adamson, Rachel and Maitland, Norman and Bangma, Chris H},
title = {Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer},
journal = {Human Gene Therapy Clinical Development},
year = {2014},
doi = {10.1089/hum.2013.181}
}
EUVIMED